Country Club Trust Company n.a. lessened its stake in shares of Novartis AG (NYSE:NVS) by 6.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,861 shares of the company’s stock after selling 4,798 shares during the quarter. Country Club Trust Company n.a.’s holdings in Novartis were worth $5,697,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in NVS. Beach Investment Management LLC. bought a new position in shares of Novartis during the 2nd quarter worth about $5,592,000. JPMorgan Chase & Co. boosted its position in shares of Novartis by 14.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 612,178 shares of the company’s stock worth $51,098,000 after purchasing an additional 78,301 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Novartis by 2.7% during the 2nd quarter. Alliancebernstein L.P. now owns 56,504 shares of the company’s stock worth $4,716,000 after purchasing an additional 1,483 shares in the last quarter. Matthew Goff Investment Advisor LLC boosted its position in shares of Novartis by 10.2% during the 2nd quarter. Matthew Goff Investment Advisor LLC now owns 23,506 shares of the company’s stock worth $1,962,000 after purchasing an additional 2,173 shares in the last quarter. Finally, South State Corp boosted its position in shares of Novartis by 7.3% during the 2nd quarter. South State Corp now owns 46,513 shares of the company’s stock worth $3,882,000 after purchasing an additional 3,157 shares in the last quarter. 10.85% of the stock is currently owned by institutional investors.
Novartis AG (NYSE NVS) traded up $1.01 on Friday, hitting $86.68. 831,754 shares of the company were exchanged, compared to its average volume of 990,200. The company has a quick ratio of 0.81, a current ratio of 1.08 and a debt-to-equity ratio of 0.32. Novartis AG has a 12 month low of $69.53 and a 12 month high of $86.90. The firm has a market cap of $225,470.00, a price-to-earnings ratio of 30.85, a PEG ratio of 2.55 and a beta of 0.74.
Novartis (NYSE:NVS) last posted its earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.04. The company had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The firm’s revenue was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.23 EPS. sell-side analysts predict that Novartis AG will post 4.77 earnings per share for the current fiscal year.
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 price objective on the stock in a research report on Tuesday, September 19th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, October 24th. Barclays cut shares of Novartis from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, October 25th. Bank of America cut shares of Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th. Finally, Nord/LB reissued a “neutral” rating on shares of Novartis in a research report on Wednesday, December 27th. Five analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $85.32.
WARNING: This report was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://ledgergazette.com/2018/01/12/novartis-ag-nvs-shares-sold-by-country-club-trust-company-n-a.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.